DeepMed Research

The Gynecologic Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1970-01-01

Employees: 11

Market Cap: -

Website: http://www.gog.org

Clinical Trials

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2007-12-07

Last Posted Date: 2018-07-18

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 71

Registration Number: NCT00569673

Locations: 🇺🇸
St. John's Regional Health Center, Springfield, Missouri, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States

and more 34 locations

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Not Applicable

Withdrawn

Conditions: Primary Peritoneal Carcinoma
Stage III Ovarian Cancer
Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Stage IV Ovarian Cancer

Interventions: Drug: Cyclophosphamide
Procedure: Laboratory Biomarker Analysis
Biological: Oregovomab

First Posted Date: 2007-10-30

Last Posted Date: 2017-07-14

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00551265

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors

Phase 2

Completed

Conditions: Complete Hydatidiform Mole
Non-Metastatic Gestational Trophoblastic Tumor
Partial Hydatidiform Mole

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2007-08-27

Last Posted Date: 2017-08-24

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 64

Registration Number: NCT00521118

Locations: 🇺🇸
Women's Cancer Center of Nevada, Las Vegas, Nevada, United States
🇺🇸
University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States

and more 26 locations

Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia

Phase 2

Terminated

Conditions: High Grade Squamous Intraepithelial Neoplasia
Stage 0 Uterine Corpus Cancer

Interventions: Procedure: Biopsy
Other: Laboratory Biomarker Analysis
Drug: Megestrol Acetate
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2007-07-19

Last Posted Date: 2020-11-03

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 9

Registration Number: NCT00503581

Locations: 🇺🇸
Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States
🇺🇸
Rush - Copley Medical Center, Aurora, Illinois, United States

and more 47 locations

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Carcinoma
Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation

First Posted Date: 2007-07-11

Last Posted Date: 2018-01-11

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 51

Registration Number: NCT00499252

Locations: 🇺🇸
University of Texas Medical Branch at Galveston, Galveston, Texas, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇺🇸
Beebe Medical Center, Lewes, Delaware, United States

and more 17 locations

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Recurrent Cervical Carcinoma
Cervical Squamous Cell Carcinoma

Interventions: Biological: Cetuximab

First Posted Date: 2007-07-11

Last Posted Date: 2015-01-13

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 38

Registration Number: NCT00499031

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Colorado Gynecologic Oncology Group, Aurora, Colorado, United States

and more 19 locations

Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172

Not Applicable

Withdrawn

Conditions: Ovarian Cancer

First Posted Date: 2007-05-24

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00477867

Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes

Completed

Conditions: Cervical Adenosquamous Carcinoma
Stage IB Cervical Cancer
Stage IIA Cervical Cancer
Stage III Cervical Cancer
Cervical Small Cell Carcinoma
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Stage IVA Cervical Cancer
Cervical Adenocarcinoma
Stage IIB Cervical Cancer

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Lymphadenectomy

First Posted Date: 2007-04-13

Last Posted Date: 2017-08-24

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 159

Registration Number: NCT00460356

Locations: 🇺🇸
Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Women's Cancer Center of Nevada, Las Vegas, Nevada, United States

and more 15 locations

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: mifepristone

First Posted Date: 2007-04-11

Last Posted Date: 2018-07-18

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 24

Registration Number: NCT00459290

Locations: 🇺🇸
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States
🇺🇸
Kaiser Permanente Medical Center - Los Angeles, Los Angeles, California, United States

and more 19 locations

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Levonorgestrel
Other: Placebo

First Posted Date: 2007-03-09

Last Posted Date: 2019-11-19

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 60

Registration Number: NCT00445887

Locations: 🇺🇸
Elkhart Clinic, Elkhart, Indiana, United States
🇺🇸
Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States
🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

and more 63 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy